• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

4
1

CATEGORIES

  • 10
  • 5
  • 1
  • 1
  • 1

PRICE

4
4
13
18

PUBLISHED

1
3
11
18

PRODUCT TYPE

12
6

Search "Prosensa Therapeutics-Detailed Product Pipeline" returned 18 results.

PRODUCT TITLE

Prosensa Therapeutics B.V. - Product Pipeline Review - 2013

Prosensa Therapeutics B.V. - Product Pipeline Review - 2013 Summary “Prosensa Therapeutics B.V. - Product Pipeline Review - 2013” provides data on the Prosensa Therapeutics B.V.’s research and development...

August 2013
FROM
Prosensa Therapeutics B.V. - Product Pipeline Review - 2012 Prosensa Therapeutics B.V. - Product Pipeline Review - 2012 - Product Thumbnail Image

Prosensa Therapeutics B.V. - Product Pipeline Review - 2012

Prosensa Therapeutics B.V. – Product Pipeline Review – 2012 Summary Global Market Direct’s pharmaceuticals report, “Prosensa Therapeutics B.V. - Product Pipeline Review - 2012” provides data on the...

June 2012
FROM
Prosensa Therapeutics B.V. - Product Pipeline Review - Q1 2011 Prosensa Therapeutics B.V. - Product Pipeline Review - Q1 2011 - Product Thumbnail Image

Prosensa Therapeutics B.V. - Product Pipeline Review - Q1 2011

Prosensa Therapeutics B.V. – Product Pipeline Review – Q1 2011 Summary Global Market Direct’s pharmaceuticals report, “Prosensa Therapeutics B.V. - Product Pipeline Review - Q1 2011” provides data...

March 2011
FROM

Prosensa Therapeutics B.V. - Product Pipeline Review - 2014

Prosensa Therapeutics B.V. - Product Pipeline Review - 2014 Summary This, ‘Prosensa Therapeutics B.V. - Product Pipeline Review - 2014’, provides an overview of the Prosensa Therapeutics B.V.’s pharmaceutical...

October 2014
FROM

Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma

“Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma” provides insights into the unmet needs in the pharmaceutical and healthcare market and potential segments where...

February 2010
FROM
Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies - Product Thumbnail Image

Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies

The successful introduction of orphan products in Europe remains problematic for the developers, although they can seek to alleviate some of the issues by carefully developing a launch strategy The...

November 2011
FROM

The Neurotechnology Industry 2013 Report

Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets...

August 2013
FROM

Duchenne Muscular Dystrophy - Pipeline Review, H2 2014

Duchenne Muscular Dystrophy - Pipeline Review, H2 2014 Summary This, ‘Duchenne Muscular Dystrophy - Pipeline Review, H2 2014’, provides an overview of the Duchenne Muscular Dystrophy’s therapeutic...

July 2014
FROM

Duchenne Muscular Dystrophy - Pipeline Review, H1 2014

Duchenne Muscular Dystrophy - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Pipeline Review, H1 2014’, provides an overview of the Duchenne Muscular Dystrophy’s...

February 2014
FROM

Myotonic Dystrophy - Pipeline Review, H2 2014

Myotonic Dystrophy - Pipeline Review, H2 2014 Summary This, ‘Myotonic Dystrophy - Pipeline Review, H2 2014’, provides an overview of the Myotonic Dystrophy’s therapeutic pipeline. This report provides...

December 2014
FROM

Huntington's Disease - Pipeline Review, H2 2014

Huntington's Disease - Pipeline Review, H2 2014 Summary This, ‘Huntington's Disease - Pipeline Review, H2 2014’, provides an overview of the Huntington's Disease’s therapeutic pipeline. This report...

August 2014
FROM

Myotonic Dystrophy - Pipeline Review, H1 2014

Myotonic Dystrophy - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Myotonic Dystrophy - Pipeline Review, H1 2014’, provides an overview of the Myotonic Dystrophy’s therapeutic pipeline. This...

June 2014
FROM

Huntington's Disease - Pipeline Review, H1 2014

Huntington's Disease - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Huntington's Disease - Pipeline Review, H1 2014’, provides an overview of the Huntington's Disease’s therapeutic pipeline. This...

February 2014
FROM
Muscular Dystrophy - Pipeline Review, H2 2014 Muscular Dystrophy - Pipeline Review, H2 2014 - Product Thumbnail Image

Muscular Dystrophy - Pipeline Review, H2 2014

Muscular Dystrophy - Pipeline Review, H2 2014 Summary This, ‘Muscular Dystrophy - Pipeline Review, H2 2014’, provides an overview of the Muscular Dystrophy’s therapeutic pipeline. This report provides...

December 2014
FROM

Pharming Group N.V. (PHARM) - Financial and Strategic SWOT Analysis Review

Pharming Group N.V. (PHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled...

November 2014
FROM
AVI BioPharma Inc. (AVII) - Financial and Strategic SWOT Analysis Review AVI BioPharma Inc. (AVII) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

AVI BioPharma Inc. (AVII) - Financial and Strategic SWOT Analysis Review

AVI BioPharma Inc. (AVII) - Financial and Strategic SWOT Analysis Review Summary AVI BioPharma, Inc. (AVI) is a biopharmaceutical company engaged in the discovery and development of RNA based drugs...

September 2011
FROM

PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding

PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding Summary Our "PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in...

March 2014
FROM

The Neurotechnology Industry 2014 Report

Now in its 10th year, The Neurotechnology Industry 2014 Report is an expanded and updated 650 page report of brain and nervous system markets and treatments It is the only publication to provide a comprehensive...

July 2014
FROM
Loading Indicator

Our Clients

Goodyear Tire & Rubber Company GlaxoSmithKline PLC Hilton Worldwide Hewlett-Packard Company Accenture PLC. Qualcomm Incorporated UBS AG